Table 3.

Effects of protopanaxadiol on thrombin-induced human platelet aggregation

Treatment (μM)	Aggregation (%)	Treatment (μM)	Aggregation (%)
Thrombin (0.05 U/mL)	86.7 ± 1.5	–	–
Ginsenoside Ra1		Ginsenoside Rd
50	83.3 ± 1.2	50	85.0 ± 3.0
10	83.0 ± 1.7	100	84.0 ± 1.7
200	83.0 ± 1.0	200	86.3 ± 1.5
300	86.7 ± 1.5	300	84.3 ± 4.0
Ginsenoside Rb1		Ginsenoside Rg3 (20R)
50	83.0 ± 1.7	50	86.7 ± 1.5
100	84.3 ± 0.6	100	86.0 ± 2.0
200	85.3 ± 3.1	200	75.7 ± 3.2
300	83.0 ± 3.5	300	62.0 ± 2.0
Ginsenoside Rb2		Ginsenoside Rg3 (20S)
50	86.7 ± 1.5	50	79.7 ± 2.1 *
100	84.7 ± 0.6	100	39.7 ± 2.1 **
200	86.3 ± 2.1	200	9.7 ± 2.1 **
300	84.7 ± 0.6	300	3.7 ± 1.5 **
Ginsenoside Rb3		Ginsenoside Rh2 (20R)
50	82.3 ± 3.5	50	83.3 ± 1.2
100	85.7 ± 1.2	100	84.7 ± 0.6
200	83.7 ± 1.5	200	85.3 ± 3.1
300	84.0 ± 3.6	300	81.0 ± 1.7
Ginsenoside Rc
50	84.7 ± 3.2	–	–
100	84.7 ± 0.6	–	–
200	86.3 ± 2.1	–	–
300	84.0 ± 2.6	–	–

Results are expressed as percentage of aggregation induced by thrombin. The data are expressed as the mean ± standard deviation (n = 4)

*p < 0.05, **p < 0.01 versus the thrombin-stimulated human platelets